United Kingdom· GB-APID-45839511000001107
Vyloy 300mg powder for concentrate for solution for infusion vials
A zolbetuximab product containing zolbetuximab, registered in United Kingdom by Astellas Pharma Ltd. The same ATC class is registered in 13 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Zolbetuximab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FX31 (zolbetuximab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 8 of them publish a price we can compare per daily dose
Zolbetuximab · ATC L01FX31
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Zolbetuximab
- Manufacturer
- Astellas Pharma Ltd
- Country
- United Kingdom (GB)
- ATC code
- L01FX31
- ATC class
- Zolbetuximab
- Defined daily dose
- 51.4 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin5013346010188
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Zolbetuximab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumVyloy 300 mgAstellas Pharma Europe
- SwitzerlandVyloy 300 mg, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungAstellas Pharma AG
- CzechiaVYLOYAstellas Pharma Europe B.V., Leiden
- SpainVYLOY 300 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONAstellas Pharma Europe B.V.
- FinlandVyloyAstellas Pharma Europe B.V.
- NorwayVyloyAstellas Pharma Europe B.V
- PolandVyloyAstellas Pharma Europe B.V.
- SwedenVyloy 300 mg Pulver till koncentrat till infusionsvätska, lösningAstellas Pharma Europe BV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vyloy
- Liechtenstein · Vyloy
- Norway · Vyloy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8bad780d-11df-450f-b8bb-08f00fdfbc69 GET /v1/drugs/8bad780d-11df-450f-b8bb-08f00fdfbc69?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "45839511000001107",
"desc": "Vyloy 300mg powder for concentrate for solution for infusion vials (Astellas Pharma Ltd)",
"form": "Powder for solution for infusion",
"vpid": "45988711000001106",
"source": "dmd",
"vtm_id": "43532811000001106",
"strength": "300 mg",
"substance": "Zolbetuximab",
"ingredient": "Zolbetuximab",
"supplier_code": "2066301000001100"
}See everything about zolbetuximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.